

Reference number(s)
2658-H

SPECIALTY QUANTITY LIMIT PROGRAM

ONPATTRO (patisiran)

I. PROGRAM DESCRIPTION

The standard limit is designed to allow a quantity sufficient for the most common uses of the medication. The recommended dosing parameters for the FDA-approved indication fall within the standard limits. Coverage of an additional quantity may be reviewed on a case-by-case basis upon request.

II. COVERED QUANTITIES

Medication	Standard Limit	FDA-recommended dosing
Onpattro (patisiran) 10mg/5mL (2mg/mL) single dose vial, solution for intravenous infusion	30mg (or 3 vials) per 21 days	For patients weighing less than 100 kg, the recommended dosage is 0.3 mg/kg once every 3 weeks. For patients weighing 100 kg or more, the recommended dosage is 30 mg once every 3 weeks.

REFERENCES

1. Onpattro [package insert]. Cambridge, MA: Alnylam Pharmaceuticals, Inc.; August 2018.